Jianming He

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 11

Top Topics

Multiple Myeloma

Newly Diagnosed

Prognostic Factors

Top Venues

Advances in therapy

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Binod Dhakal, Hermann Einsele, Jordan M Schecter, William Deraedt, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, Sandhya Nair, Jianming He, Akshay Kharat, Patricia Cost, Satish Valluri, Kwee L Yong
Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database. Blood advances (2024)
Jianming He, Heather Berringer, Bart Heeg, Haoyao Ruan, Tobias Kampfenkel, Harikumaran R Dwarakanathan, Stephen Johnston, João Mendes, Annette Lam, Sacheeta Bathija, Eric Mackay
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma. Advances in therapy 39 (9) (2022)
Mahmoud Hashim, Talitha Vincken, Florint Kroi, Samron Gebregergish, Mike Spencer, Jianping Wang, Tobias Kampfenkel, Annette Lam, Jianming He
A systematic review of noninferiority margins in oncology clinical trials. Journal of comparative effectiveness research 10 (6) (2021)
Jianming He, Ashley Duenas, Hannah Collacott, Annette Lam, Katharine S Gries, Robin Carson, Dietrich Potthoff, Nicola Trevor, Tommi Tervonen
Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany. The patient 14 (5) (2021)
John Mascarenhas, Maneesha Mehra, Jianming He, Ravi Potluri, Christina Loefgren
Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis. Journal of medical economics 23 (7) (2020)
Dolly A Parasrampuria, Jianming He, Liping Zhang, Bogdan Muresan, Peter Hu, Sepideh Nemat, Mahmoud Hashim, Annette Lam, Carlos Appiani, Michele Cavo, Meletios A Dimopoulos, Jesus San-Miguel, Maria-Victoria Mateos-Manteca
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis. British journal of haematology 189 (5) (2020)
Philippe Moreau, Cyrille Hulin, Sonja Zweegman, Mahmoud Hashim, Yannan Hu, Bart Heeg, Carla de Boer, Veronique Vanquickelberghe, Tobias Kampfenkel, Jianming He, Annette Lam, Sarah Cote, Pieter Sonneveld
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching. EJHaem 2 (1) (2020)
Pieter Sonneveld, María-Victoria Mateos, Adrian Alegre, Thierry Facon, Cyrille Hulin, Mahmoud Hashim, Talitha Vincken, Tobias Kampfenkel, Sarah Cote, Jianming He, Annette Lam, Philippe Moreau
Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible. EJHaem 1 (2) (2020)
Philippe Moreau, Benjamin Hebraud, Thierry Facon, Xavier Leleu, Cyrille Hulin, Mahmoud Hashim, Yannan Hu, Denis Caillot, Lofti Benboubker, Sonja Zweegman, Maximilian Merz, Katja Weisel, Hans Salwender, Elias K Mai, Hartmut Goldschmidt, Uta Bertsch, Véronique Vanquickelberghe, Tobias Kampfenkel, Carla de Boer, Stanimira Krotneva, Irina Proskorovsky, Jianming He, Annette Lam, Charlene Lee, Sarah Cote, Pieter Sonneveld
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. Immunotherapy 13 (2) (2020)
Jianming He, Luke Schmerold, Rian Van Rampelbergh, Lugui Qiu, Ravi Potluri, Anandaroop Dasgupta, Lin Li, Yunan Li, Peter Hu, Sepideh Nemat, Steven S Smugar, Paul Zeltzer, Carlos Appiani, Qing Li, Maneesha Mehra, Ute Richarz
Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myeloma. Advances in therapy 38 (1) (2020)
Maria-Victoria Mateos-Manteca, Jesús San F Miguel, Hartmut Goldschmidt, Pieter Sonneveld, Meletios- Athanasios Dimopoulos, Bart Heeg, Mahmoud Hashim, William Deraedt, Peter Hu, Annette Lam, Jianming He
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Leukemia & lymphoma 61 (3) (2019)